AVITA Medical, Inc. (NASDAQ:RCEL) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Investor Relations James Corbett - Chief Executive Officer Sean Ekins - Acting Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen Phillip Dantoin - Piper Sandler Ryan Zimmerman - BTIG Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. First Quarter 2023 Earnings Conference Call. At this time all participants are in a lis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiza ...

AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Jim Corbett - Chief Executive Officer Sean Ekins - Acting Chief Financial Officer Conference Call Participants Joshua Jennings - Cowen Phillip Dantoin - Piper Brooks O'Neil - Lake Street Capital Markets Lyanne Harrison - Bank of America Operator Good day and thank you for standing by. Welcome to AVITA Medical Fourth Quarter 2022 Earnings ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 28159 Avenue Stanford Suite 220 Valencia, CA 91355 (Address of principal ...

AVITA Medical, Inc. (NASDAQ:RCEL) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Jim Corbett - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Charlie Montang - Lake Street Capital Matthew O’Brien - Piper Sandler Ryan Zimmerman - BTIG Joshua Jennings - Cowen Madeleine Williams - Wilsons Operator Good day and thank you for standing by and welcome to AVITA Medical Third Qua ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File Number: 001-39059 AVITA MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 85-1021707 (IRS Employer Identification No.) 28159 Avenue Stanford FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION ...

Financial Data and Key Metrics Changes - The company reported record commercial RECELL revenues of $8.2 million for Q2 2022, a 23% increase from $6.7 million in the same quarter last year [9] - Total revenue for Q2 2022 was $8.3 million, down from $10.3 million in the prior year, which included $3.6 million in BARDA revenue [32] - Gross profit margin improved by 3% to 83% compared to the prior year [33] - Net loss increased by 33% to $6.3 million, or $0.25 per share, compared to a net loss of $4.7 million, or $0.19 per share, in the prior year [35] - Adjusted EBITDA loss increased by 51% to $4.7 million compared to $3.1 million in the prior year [36] Business Line Data and Key Metrics Changes - Commercial revenue for the first half of 2022 was $15.7 million, a 39% increase from $11.3 million in the same period last year [10] - The company achieved greater penetration and a larger base of accounts, leading to an increase in burn cases treated with RECELL [11] - The outpatient market is expected to become a larger portion of the addressable market, with ongoing efforts to familiarize centers with outpatient care pathways [14] Market Data and Key Metrics Changes - In Japan, the company completed its first training and evaluation cases during the quarter, with ongoing discussions regarding reimbursement and pricing [15] - The company anticipates that outpatient treatment will comprise the core soft tissue market, supporting continued growth [14] Company Strategy and Development Direction - The company is focused on driving healthcare provider engagement through education and maintaining momentum in burn treatments [28] - Plans to submit PMA supplements for soft tissue reconstruction and vitiligo indications by the end of 2022, with market entry anticipated in the second half of 2023 [29] - The company aims to leverage its existing infrastructure to launch RECELL in trauma centers co-located with burn centers [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving projected commercial revenue of approximately $30 million for 2022, representing a 20% year-over-year increase [42] - Concerns were raised regarding potential supply chain issues, macroeconomic factors, and staffing shortages in hospitals affecting growth [55] - Management noted that labor shortages have stabilized but have not improved, with increased training efforts to address staffing challenges [56] Other Important Information - The company is developing an automated RECELL device to improve efficiency in dermatology practices [24] - The RECELL system is expected to differentiate itself in the vitiligo market due to its strong safety record and treatment procedure [26] Q&A Session Summary Question: Clarification on soft tissue trial data and non-inferiority - Management explained that while donor skin sparing was statistically significant, non-inferiority for healing was not met at the pre-specified level, but they remain confident in the PMA submission [45][46] Question: Safety events in the study - Management confirmed that there were no differences in adverse events between the control and treated groups [49] Question: Updates on vitiligo trial data presentation - Management indicated that top-line data from the vitiligo trial would be released shortly, and they are currently pursuing a go-it-alone strategy for commercialization [51] Question: Guidance for the second half of the year - Management reiterated confidence in the $30 million revenue guidance, citing seasonality and external factors as reasons for not increasing guidance [55] Question: Labor shortages and improvements - Management noted that while labor shortages have stabilized, they have not improved, and training efforts have increased to address this issue [56] Question: Adoption and reimbursement in Japan - Management expressed optimism about reimbursement discussions in Japan and indicated that they expect favorable pricing [63][64] Question: Maintenance of gross margins - Management stated that they aim to maintain gross margins at the low 80% level moving forward [67]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or Delaware 85-1021707 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 28159 Avenue Stanford Suite 220 Valencia, CA 91355 (Address of principal executive offices and Zip Code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

One Platform. Endless Possibilities. May 2022 NASDAQ: RCEL ASX: AVH ©Copyright 2022 AVITA Medical. All Rights Reserved. Legal Disclaimers Certain statements in this presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development str ...

AVITA Medical, Inc. (NASDAQ:RCEL) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Caroline Corner - Managing Director, Investor Relations Mike Perry - Chief Executive Officer Michael Holder - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Lyanne Harrison - Bank of America John Hester - Bell Potter Operator Good day and thank you for standing by. Welcome to the AVITA Medical Inc. First Quarter 2022 ...